More encouraging news about potential hemophilia therapeutics emerged this week, with Sanofi announcing “unprecedented” phase 3 data on efanesoctocog alfa, a bioengineered clotting factor, and fitusiran, an RNA therapeutic that lowers antithrombin.
Source: Drug Industry Daily